This review summarizes the changes in the 5th edition of the WHO Classification of
Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new …

The family of the neurotrophic tropomyosin kinase receptors (NTRK or TRK) is a part of the
transmembrane tyrosine kinases responsible for neuronal development. The members of …

Objective Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with
demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the …

The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs)
has undergone major advancements in the last decade, causing a paradigm shift in the …

Papillary thyroid carcinoma is the most common type of thyroid malignancy both in adults
and pediatric population. Since the 1980s, there are changes in criteria in labelling thyroid …

NTRK-rearranged mesenchymal neoplasms mostly affect the soft tissues of pediatric
patients. Given the responsiveness to selective NTRK inhibitors, it remains critical to identify …

Background: BRAFV600E and N/H/K RAS mutations and oncogenic kinase fusions
involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase …

Over the past 3 decades, advances in the molecular genetics of thyroid cancer (TC) have
been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main …

Oncogenic fusion proteins, arising from chromosomal rearrangements, have emerged as
prominent drivers of tumorigenesis and crucial therapeutic targets in cancer research. In …

Radioiodine (RAI) refractory differentiated thyroid cancer is an uncommon and challenging
situation that requires a multidisciplinary approach to therapeutic strategies. The definition of …